

14. Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. *J Gen Intern Med* 1993; **8**: 289–94.
15. Wahr JA, Abernathy 3rd JH, Lazarra EH, et al. Medication safety in the operating room: literature and expert-based recommendations. *Br J Anaesth* 2017; **118**: 32–43.
16. Kohn LT, Corrigan JM, Donaldson MS. *To Err is human: building a safer health system*. Washington, DC: National Academy Press; 1999.
17. Roeder N, Wächter C. Bedeutung von Humanfaktoren im Qualitäts- und Risikomanagement in Medizin und Luftfahrt. *Das Krankenhaus* 2015; **107**: 126–36.
18. Sexton JB, Thomas EJ, Helmreich RL. Error, stress, and teamwork in medicine and aviation: cross sectional surveys. *Br Med J* 2000; **320**: 745–9.
19. Avidan A, Levin PD, Weissman C, Gozal Y. Anesthesiologists' ability in calculating weight-based concentrations for pediatric drug infusions: an observational study. *J Clin Anesth* 2014; **26**: 276–80.
20. Calhoun AW, Boone MC, Porter MB, Miller KH. Using simulation to address hierarchy-related errors in medical practice. *Perm J* 2014; **18**: 14–20.
21. Eichhorn JH. Medication safety in the operating room: time for a new paradigm. APSF Summit Conference Proceedings. *APSF Newsl* 2010; **25**: 1–20.

doi: [10.1016/j.bja.2017.12.008](https://doi.org/10.1016/j.bja.2017.12.008)

Advance Access Publication Date: 17 January 2018

© 2018 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

Evidence of residual neuromuscular block with sugammadex vs neostigmine

A. Abad-Gurumeta

E-mail: alfredoabadgurumeta@gmail.com.

Editor—We read with interest the narrative review of Hunter, but we do not agree with the statement 'As yet, there is no evidence that the incidence of postoperative pulmonary complications is lower after use of sugammadex rather than an anticholinesterase'.¹ In recent years, numerous clinical trials analysed in meta-analyses have shown a decreased incidence of respiratory events and residual curarization in patients treated with sugammadex compared with neostigmine.^{2–4} Moreover, fewer adverse effects were observed in the sugammadex group.^{2–4} Although no statistically significant differences have been demonstrated with critical high-risk respiratory events, minor complications do seem to be reduced.^{2–4}

Declaration of interest

None declared.

Funding

None.

References

1. Hunter JM. Reversal of residual neuromuscular block: complications associated with perioperative management of muscle relaxation. *Br J Anaesth* 2017; **119**: i53–62.
2. Abad-Gurumeta A, Ripollés-Melchor J, Casans-Francés R, et al. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. *Anaesthesia* 2015; **70**: 1441–52.
3. Carron M, Zarantonello F, Tellaroli P, Ori C. Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. *J Clin Anesth* 2016; **35**: 1–12.
4. Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. *Cochrane Database Syst Rev* 2017; **14**: CD012763.

doi: [10.1016/j.bja.2017.12.020](https://doi.org/10.1016/j.bja.2017.12.020)

Advance Access Publication Date: 17 January 2018

© 2017 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.